Mirati
Presence
Mirati is one of the...
Mirati is a company listed under the stock ticker MRTX (US).
Acquisition, funding and merger involving Mirati.
- Bristol-Myers Squibb has announced the acquisition of Mirati (posted on October 12 2023).
Executives
View the org chart displaying its 29 main executives
Most searched biographies at Mirati
- Charles Baum, Interim Chief Executive Officer
- Maya Martinez-Davis, Director
- Julie Cherrington, Director
Popular executive movements at Mirati
- Laurie Stelzer, Chief Financial Officer, will leave the company on Sep. 8, 2023 (posted on August 24 2023).
- Aaron Ondrey who is Senior Vice President, Financial Planning and Analysis, will be promoted to Interim Chief Financial Officer on Sep. 8, 2023 (posted on August 24 2023).
- David Meek, Chief Executive Officer, has left the company (posted on August 9 2023).
Click here to view some more movements at Mirati
Create your alert
to follow the executive moves at Mirati.
Biotechnology
Mirati has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).
Popular M&A news in Biotechnology
- Karius has just announced a $100 Million fundraising (posted on May 3 2024).
- Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
- WindRose Health Investors has announced the acquisition of SubjectWell (posted on May 2 2024).
Popular contacts in Biotechnology
News
Press releases by Mirati
- Mirati Therapeutics Inc. - European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
- Mirati Therapeutics Inc. - Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination P
- Mirati Therapeutics Inc. - Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- Mirati Therapeutics Inc. - Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASG12C-Mutated NSCLC
- Mirati Therapeutics Inc. - Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
- Mirati Therapeutics Inc. - Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio with Acquisition of Mirati Therapeutics
- Mirati Therapeutics Inc. - Mirati To Present Updated Clinical Data at ESMO Congress 2023
- Mirati Therapeutics Inc. - Mirati Presents Two-Year Follow-Up Data from KRYSTAL-1 Study Demonstrating Durable Response and Long-Term Overall Survival at 2023 World Conference on Lung Cancer
- Mirati Therapeutics Inc. - Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
- Mirati Therapeutics Inc. - Mirati Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
- View more press releases Close
Social media about Mirati
- Mirati on Wikipedia, Google News & Yahoo Finance
- Mirati on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Charles Baum 
